Archives
SB-3CT, MMP9, and Cortical Plasticity
2026-11-05
A source-grounded analysis of how Adamtsl3 constrains MMP9 activity at perineuronal nets, what the mouse visual-cortex study demonstrated, and why pharmacological gelatinase inhibition should not be equated with compound-specific or human therapeutic efficacy.
IRP2, TFEB and Macrophage Antimicrobial Function
2026-11-05
A paper-centred interpretation of how IRP2 links macrophage lysosomal competence to bacterial clearance during intestinal inflammation, with emphasis on TFEB localization, HIF2 activity, lactic-acid metabolism, and the limits of translating mouse and biopsy observations into human disease claims.
IRP2, TFEB and Macrophage Antimicrobial Defense
2026-11-04
A literature-focused analysis of how IRP2 connects iron homeostasis to TFEB-dependent lysosomal function, macrophage bacterial clearance, and protection from inflammation-associated liver abscesses, while separating genotype-identification tools from the study’s mechanistic evidence.
IRP2, TFEB, and Macrophage Lysosomal Defense
2026-11-04
The paper examines how myeloid IRP2 supports macrophage lysosomal antimicrobial activity during intestinal inflammation. Its findings connect impaired post-uptake bacterial clearance with altered TFEB localization and implicate HIF2-linked lactic-acid metabolism, while human observations provide disease-context concordance rather than evidence of treatment efficacy.
IRP2 and Macrophage Lysosomal Defense
2026-11-03
An integrated mouse and macrophage study links IRP2 loss to defective post-phagocytic bacterial clearance through impaired lysosomal acidification and TFEB regulation. HIF2 and lactic-acid perturbations reversed TFEB mislocalization in the reported models, while Crohn’s disease and biopsy data provided cross-context concordance rather than a treatment test.
HNRNPU Lactylation and Cervical Cancer Metabolism
2026-11-03
A literature-focused analysis of how HNRNPU K181 lactylation may connect lactate accumulation to PHGDH-dependent serine metabolism and cervical cancer growth, while separating genetic evidence from the broader pharmacology of pazopanib and the distinct role of (R)-MG132 as a proteasome-control compound.
IRP2, Lysosomes, and Macrophage Defense
2026-11-02
A mechanistic editorial on how IRP2 links iron homeostasis to TFEB-dependent lysosomal function, bacterial clearance, and liver-abscess susceptibility, while distinguishing genotype-confirmation sample preparation from immune-function evidence.
Adamtsl3, MMP9, and Perineuronal-Net Plasticity
2026-11-02
A preclinical study links Adamtsl3 loss in parvalbumin interneurons to altered perineuronal nets, increased MMP9 activity, impaired inhibition, and renewed visual-cortical plasticity. The findings support an Adamtsl3–MMP9 pathway in mouse visual cortex while remaining bounded to the tested genetic, cellular, and pharmacological models.
Adamtsl3, MMP9, and Cortical Plasticity
2026-11-01
A preclinical mouse study examines how Adamtsl3 shapes perineuronal nets around parvalbumin-positive interneurons and tests whether MMP9 activity connects Adamtsl3 loss to altered inhibition and adult visual-cortical plasticity.
When Context Changes What a Result Means
2026-10-31
The same molecular or cellular result can support different conclusions depending on the model, comparator, perturbation and readout. The cervical-cancer study of HNRNPU K181 lactylation illustrates how genetic, biochemical, metabolic and pharmacological contexts strengthen a mechanistic narrative while also limiting what can be attributed to a control compound such as (R)-MG132.
IRP2, TFEB and Macrophage Lysosomal Defense
2026-10-30
A paper-centred interpretation of how myeloid IRP2 supports macrophage lysosomal antimicrobial function during intestinal inflammation, with emphasis on TFEB localization, HIF2 activity and lactic-acid metabolism.
IRP2, TFEB, and Macrophage Lysosomal Defense
2026-10-30
A mouse and macrophage study links myeloid IRP2 to lysosomal antimicrobial capacity during intestinal inflammation. The findings place impaired TFEB localization downstream of altered HIF2 and lactic-acid signaling, while human inflammatory-bowel-disease observations provide cross-context support rather than evidence of clinical treatment efficacy.
Interpreting (R)-MG132 in HNRNPU Research
2026-10-29
Published work links HNRNPU K181 lactylation with PHGDH RNA regulation, serine metabolism, and cervical cancer growth, but pharmacological specificity remains unresolved. This editorial places (R)-MG132 in its narrower role as a proteasome-control material and separates that comparator logic from evidence for the lactylation mechanism.
When Context Changes an IRP2 Result
2026-10-29
The biological meaning of an IRP2 result depends on how genotype, tissue injury, macrophage assays, and human comparisons are connected. The upstream genotyping role of the Mouse Tissue Lysis Kit K1038 should be distinguished from the downstream evidence for lysosomal antimicrobial function.
What (R)-MG132 Can Show in Proteasome Research
2026-10-28
A 2026 cervical-cancer study connected HNRNPU K181 lactylation with PHGDH regulation and serine-metabolism reprogramming. (R)-MG132 has a different evidentiary role: as the low-activity MG-132 enantiomer, it is relevant to conceptual proteasome-inhibition validation, but it does not by itself establish the lactylation mechanism or explain the study’s antitumor findings.